Study | Indication and index test | TP | FN | FP | TN | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | |
---|---|---|---|---|---|---|---|---|
Rinne and colleagues [22] | N-staging and M-staging | PET | 4 | 0 | 11 | 37 | 100 (40 to 100) | 77 (63 to 88) |
Crippa and colleagues [27] | N-staging | PET | 17 | 2 | 3 | 16 | 90 (66.9 to 98.7)b | 84 (60.4 to 96.6)b |
Eigtved and colleagues [24] | M-staging | PET | 28 | 1 | 4 | 5 | 97 (82 to 100) | 56 (21 to 86) |
Klein and colleagues [21] | N-staging | PET | 2 | 1 | 0 | 14 | 67 (9.4 to 99.2)b | 100 (76.8 to 100)b |
Acland and colleagues [18] | N-staging | PET | 0a | 14a | 7a | 29a | 0 (0 to 23.2)b | 80,6b (64.0 to 91.8)b |
Belhocine and colleagues [19] | N-staging | PET | 1a | 5a | 1a | 14b | 16.7b (0.4 to 64.1)b | 93.3b (68.1 to 99.8)b |
Reinhardt and colleagues [29] | M-staging | PET | 23 | 2 | 1 | 41 | 92 (74.0 to 99.0)b | 98 (87.4 to 99.9)b |
Hafner and colleagues [25] | M-staging | PET | 0 | 0 | 2 | 98 | – | 98 d (93.0 to 99.8)d |
N-staging | PET | 2 | 24 | 0 | 74 | 8 (0.9 to 25.1)b | 100 (95.1 to 100)b | |
Fink and colleagues [20] | N-staging | PET | 1 | 7 | 0 | 40 | 13 (0 to 53) | 100 (91 to 100) |
Vereecken and colleagues [26] | N-staging | PET | 4a | 6a | 27a | 6a | 40.0b (12.2 to 73.8)b | 18.2b (7.0 to 35.5)b |
Brady and colleagues [45] | N-staging and M-staging | PET | 30 | 14 | 5 | 54 | 68 (52 to 81) | 92 (81 to 97) |
Maubec and colleagues [28] | N-staging and M-staging | PET/CT | 1b | 5b | 5 | 14 | 17 (0.4b to 64) | 74 (49 to 91) |
Strobel and colleagues [36] | N-staging and M-staging | PET/CT | 45 | 8 | 3 | 68 | 85 (72.4 to 93.3)b | 96 (88.1 to 99.1)b |
PET/CT and separate CT | 52 | 1 | 4 | 67 | 98 (89,9 to 100)b | 94 (86.2 to 98.4)b | ||
Singh and colleagues [23] | N-staging | PET/CT | 2 | 12 | 2 | 36 | 14.3 (2.5 to 44) b | 94.7 (81 to 99) |
Bastiaannet and colleagues [35] | M-staging | PET | 68 | 11 | 11 | 161 | 86.1b (76.5 to 92.8)b | 93.6b (88.8 to 96.8)b |
CT | 61 | 17 | 11 | 162b | 78.2b (67.4 to 86.8)b | 93.6b (88.9 to 96.8)b | ||
Veit-Haibach and colleagues [37] | N-staging | PET/CT | 5b | 8 | 0 | 43b | 38.5 (14 to 68) | 100 (92 to 100) |
PET | 5b | 8 | 0 | 43b | 38.5 (14 to 68) | 100 (92 to 100) | ||
CT | 3b,c | 10 | 0 | 43b,c | 23.1 (5 to 53) | 100 (92 to 100) | ||
M-staging | PET/CT | 5b | 7 | 3 | 41b | 41.7 (15 to 72) | 93.2 (81 to 99) | |
PET | 4b | 8 | 4 | 40 b | 33.3 (9 to 65) | 90.9 (78 to 97) | ||
CT | 3b,c | 9 | 3 | 41b,c | 25.0 (5 to 57) | 93.2 (81 to 99) | ||
Aukema and colleagues [34] | N-staging | PET/CT | 26 | 4 | 1 | 39 | 86.7b (69.3 to 96.2)b | 97.5b (86.8 to 99.9)b |